GOODWILL AND INTANGIBLE ASSETS - Summary of Consideration For Asset Acquisition (Details) - XEPI Transaction - USD ($) $ in Thousands		12 Months Ended
	Nov. 06, 2025	Dec. 31, 2025
Contractual Amount
Asset Acquisition [Line Items]
Consideration transferred		$ 12,080
Contractual Amount \| Biofrontera
Asset Acquisition [Line Items]
Upfront Payment - Asset Purchase Agreement		3,000
Contractual Amount \| Biofrontera \| Contingent Consideration - Achievement of Commercial Quantities
Asset Acquisition [Line Items]
Contingent consideration	$ 1,000	1,000
Contractual Amount \| Biofrontera \| Contingent Consideration - Achievement of Sales Based Milestones
Asset Acquisition [Line Items]
Contingent consideration		$ 6,000
Contractual Amount \| Ferrer
Asset Acquisition [Line Items]
Royalty Payments on Net Sales of Xepi		7.00%
Contractual Amount \| Ferrer \| Contingent Consideration - Acceptance of Initial API Purchase
Asset Acquisition [Line Items]
Contingent consideration	$ 1,200	$ 1,200
Contractual Amount \| Various
Asset Acquisition [Line Items]
Xepi Transaction - Transaction Expenses		880
Allocated Purchase Price
Asset Acquisition [Line Items]
Consideration transferred		6,080
Allocated Purchase Price \| Biofrontera
Asset Acquisition [Line Items]
Upfront Payment - Asset Purchase Agreement		3,000
Allocated Purchase Price \| Biofrontera \| Contingent Consideration - Achievement of Commercial Quantities
Asset Acquisition [Line Items]
Contingent consideration		1,000
Allocated Purchase Price \| Biofrontera \| Contingent Consideration - Achievement of Sales Based Milestones
Asset Acquisition [Line Items]
Contingent consideration		$ 0
Allocated Purchase Price \| Ferrer
Asset Acquisition [Line Items]
Royalty Payments on Net Sales of Xepi		0.00%
Allocated Purchase Price \| Ferrer \| Contingent Consideration - Acceptance of Initial API Purchase
Asset Acquisition [Line Items]
Contingent consideration		$ 1,200
Allocated Purchase Price \| Various
Asset Acquisition [Line Items]
Xepi Transaction - Transaction Expenses		$ 880

Pelthos Therapeutics Inc. 10-K